Short Interest in Ascendis Pharma A/S (NASDAQ:ASND) Declines By 6.5%

Ascendis Pharma A/S (NASDAQ:ASND) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 3,460,000 shares, a decrease of 6.5% from the April 30th total of 3,700,000 shares. Based on an average daily volume of 370,500 shares, the short-interest ratio is currently 9.3 days.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $25,000. Private Ocean LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter worth approximately $36,000. Quadrant Capital Group LLC increased its stake in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock worth $40,000 after buying an additional 151 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 91 shares during the last quarter. Finally, Barometer Capital Management Inc. purchased a new stake in Ascendis Pharma A/S during the 4th quarter valued at $126,000.

Wall Street Analysts Forecast Growth

ASND has been the subject of a number of recent analyst reports. Citigroup lifted their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, Stifel Nicolaus initiated coverage on Ascendis Pharma A/S in a research note on Friday. They set a “buy” rating and a $200.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Moderate Buy” and a consensus target price of $179.44.

Ascendis Pharma A/S Stock Down 1.7 %

NASDAQ:ASND traded down $2.35 during midday trading on Friday, hitting $135.10. The company had a trading volume of 587,045 shares, compared to its average volume of 519,584. Ascendis Pharma A/S has a 52-week low of $83.75 and a 52-week high of $161.00. The stock’s fifty day moving average price is $138.93 and its 200-day moving average price is $133.27.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). The firm had revenue of $103.11 million during the quarter, compared to analysts’ expectations of $85.72 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. As a group, research analysts anticipate that Ascendis Pharma A/S will post -5.03 EPS for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.